Researchers at Hong Kong University's AIDS Institute found that a bispecific antibody was associated with viral control and elimination of infected cells, according to an animal study in the Journal of Clinical Investigation. The study team said the antibody could be ready for clinical trials in three to five years.
A study in the Journal of the American Heart Association found that Xarelto, or rivaroxaban, was associated with reduced rates of stroke and systemic embolism compared with warfarin in patients with nonvalvular atrial fibrillation and frailty. The risk of major bleeding was similar in the study.
Almost 1% of surgery patients who receive transfusions may develop venous thromboembolism within the next 30 days, according to a 751,000-patient study in JAMA Surgery. Further research is needed, but the data support efforts to limit blood transfusions to situations where they are necessary, said lead researcher Dr. Aaron Tobian, director of transfusion medicine at Johns Hopkins Medicine.
The SMART, or Sickle and Malaria Accurate Remote Testing, point-of-care technology platform won top honors at the Vodafone Wireless Innovation Project grant competition, and its developers will receive $300,000 over three years to continue their work. The wireless device can be used to diagnose, track and monitor patients with sickle cell disease and malaria in underserved communities and can interpret data in eight minutes.
Paraguay has been declared malaria-free, the first country in the Americas to achieve this status in 45 years, according to the World Health Organization. "Success stories like Paraguay's show what is possible. If malaria can be eliminated in one country, it can be eliminated in all countries," said WHO Director-General Tedros Adhanom Ghebreyesus.
Artemis Therapeutics presented data on its lead candidate artemisone, showing the drug effectively prevents human cytomegalovirus replication, at the 2018 annual meeting of the American Society for Microbiology. Artemisone is being developed as a first-in-class CMV treatment but also as a best-in-class malaria treatment.
Celltrion Healthcare, an affiliate of biopharmaceutical firm Celltrion, revealed that Truxima, or rituximab, a biosimilar for Roche's Mabthera, is being marketed in 18 European countries since its commercial launch in the UK last year. Truxima, an antibody biosimilar, was developed to treat rheumatoid arthritis and non-Hodgkin lymphoma, among other conditions.
Amgen's supplemental new drug application for the addition of overall survival data to the label of relapsed or refractory multiple myeloma drug Kyprolis, or carfilzomib, was approved by the FDA. The data were from the late-stage ASPIRE study in which the drug, combined with lenalidomide and dexamethasone, significantly reduced the death risk of patients by 21% and extended overall survival by 7.9 months compared with lenalidomide and dexamethasone alone.
Anna Pyayt, assistant professor of chemical and biomedical engineering at the University of South Florida, hit upon the idea of a mobile blood test lab that leverages two advanced technologies. Smartphones with their processing power and excellent cameras and Arduino microcontrollers and quick prototyping allowed her to produce a compact system that closely mimics its much larger counterpart.
DNA testing of tumor tissue has quickly gained traction to become the new standard of practice for personalizing colorectal cancer treatment, especially for metastatic disease. This piece delves into five guideline statements on specific tumor tissue biomarkers and mismatch repair testing for colorectal tumor tissue.
- Page 1